The race to produce vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) began when the first sequence was published, and this forms the basis for …

The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies
worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to
emerge during the global pandemic and may facilitate escape from current antibody …

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates …

The recently emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Beta
(B. 1.351) and Gamma (P. 1) variants of concern (VoCs) include a key mutation (N501Y) …

Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused
successive global waves of infection. These variants, with multiple mutations in the spike …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B. 1.1. 7 and B. 1.351
variants were first identified in the United Kingdom and South Africa, respectively, and have …

SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being
deployed at scale, aiming to generate responses against the virus spike. The scale of the …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
threatens efforts to contain the coronavirus disease 2019 (COVID-19) pandemic. The …

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising
concerns about the efficacy of infection-or vaccine-induced antibodies. We compared …